VEGFA and early-onset autosomal dominant Alzheimer disease: While all of these findings appear to support a potential increased risk of neurodegeneration with intravitreal anti-VEGF drug use, it is likely that this risk is relevant mostly to persons who have a high baseline risk of neurodegeneration (e.g., family history of Alzheimer’s disease, Parkinson’s disease, uncontrolled diabetes, etc.)and persons at risk of excessive VEGF inhibition with normal doses.